June 4th 2025
The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.
Data Support 177Lu-PSMA-617 Vs Cabazitaxel in Metastatic Prostate Cancer
December 21st 2023While the overall survival between patients receiving cabazitaxel and those receiving Lu-PSMA-617 had negligible difference, the results of the phase 2 TheraP trial supports the use of Lu-PSMA-617 as an alternative treatment for prostate cancer.
Docetaxel/SOC Significantly Reduces Mortality in Low PSA Prostate Cancer
November 7th 2023Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.
MAGNITUDE Trial Highlights OS Benefit with Niraparib Combo in BRCA+ mCRPC
October 22nd 2023Data from the MAGNITUDE trial support the positive benefit/risk profile of niraparib plus abiraterone acetate and prednisone as a treatment for those with BRCA-mutated metastatic castration-resistant prostate cancer.
FDA Gives Priority Review to Enzalutamide in Non-Metastatic HSPC
August 23rd 2023The FDA sets a Prescription Drug User Fee Act date in the fourth quarter of 2023 for its decision regarding enzalutamide as a treatment for those with non-metastatic hormone-sensitive prostate cancer with a high-risk of biochemical recurrence.